Realcan Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 4/6
Realcan Pharmaceutical Group has a total shareholder equity of CN¥5.7B and total debt of CN¥5.9B, which brings its debt-to-equity ratio to 102.9%. Its total assets and total liabilities are CN¥15.7B and CN¥10.0B respectively. Realcan Pharmaceutical Group's EBIT is CN¥14.1M making its interest coverage ratio -0.1. It has cash and short-term investments of CN¥4.0B.
Key information
102.9%
Debt to equity ratio
CN¥5.86b
Debt
| Interest coverage ratio | -0.1x |
| Cash | CN¥4.04b |
| Equity | CN¥5.69b |
| Total liabilities | CN¥10.03b |
| Total assets | CN¥15.73b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 002589's short term assets (CN¥10.8B) exceed its short term liabilities (CN¥9.7B).
Long Term Liabilities: 002589's short term assets (CN¥10.8B) exceed its long term liabilities (CN¥379.1M).
Debt to Equity History and Analysis
Debt Level: 002589's net debt to equity ratio (31.9%) is considered satisfactory.
Reducing Debt: 002589's debt to equity ratio has increased from 62.1% to 102.9% over the past 5 years.
Debt Coverage: 002589's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 002589 earns more interest than it pays, so coverage of interest payments is not a concern.